Molecular characterization of clear cell adenocarcinoma of the urinary bladder
Histopathology · 2026
DOI: 10.1111/his.70096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2026. Verfasst von Shilpy Jha und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Manipal Hospitals, Bangalore, India. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Adenocarcinoma, Clear Cell. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background
Clear cell adenocarcinoma (CCA) of the urinary tract is a rare genitourinary malignancy that primarily arises in the urethra and bladder. Due to its rarity, the molecular landscape of these tumours remains poorly characterized. In this large series, we aimed to molecularly characterize CCA to gain insights into its pathogenesis and identify potential targets for therapy.
Design
Formalin‐fixed, paraffin‐embedded tumour tissue blocks from 19 cases of CCA were subjected to molecular profiling using a targeted next‐generation sequencing (NGS) panel.
Results
The most common alteration was a gain‐of‐function mutation in PIK3CA (74%), followed by mutations in KRAS (26%), ERBB2 (21%), SMAD4 (21%), RB1 (16%), TP53 (5%), MET (5%) and APC (5%). Thirteen tumours harboured co‐mutations. Five cases showed concurrent PIK3CA and KRAS mutations, while the remaining tumours had either isolated PIK3CA alterations or co‐occurring loss‐of‐function mutations in tumour suppressor genes, including RB1 point mutation, SMAD4 inactivation, APC truncation or TP53 inactivation. Eight patients died of disease, with a mean follow‐up of 14 months (range, 3–31 months). Notably, all eight deceased patients and two of the surviving patients harboured PIK3CA mutations.
Conclusions
In summary, we identified a distinct oncogenic pathway in CCA of the urinary bladder, most commonly involving activation of the PI3K/AKT/mTOR pathway through gain‐of‐function mutations in PIK3CA (74%) and/or KRAS (26%). These tumours frequently harbour loss‐of‐function mutations in tumour suppressor genes ( TP53 , SMAD4 , RB1 and APC ) and point/missense mutations of proto‐oncogenes ( ERBB2 and MET ). Our study also highlights potential therapeutic targets for this aggressive malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Manipal Hospitals, Bangalore, India.
- Department of Pathology, Kapoor Centre of Urology and Pathology, Raipur, India.
- Department of Pathology, Stanford Medical Center, Stanford, California, USA.
- Department of Pathology, University of California, Irvine, California, USA.
- Department of Oncology, All India Institute of Medical Sciences, Bhubaneswar, India.
- Department of Pathology and Laboratory Medicine, CORE Diagnostics and CORE Group of Reference Laboratories, Gurgaon, India.
ORCID-Profile: Anandi Lobo, Ankur R Sangoi, Shivani R Kandukuri, Sourav K Mishra, Ekta Jain, Mahmut Akgul, Andres M Acosta, Anil V Parwani, Sean R Williamson, Liang Cheng
Zitieren
APA
Jha, S., Lobo, A., Sangoi, A. R., Kandukuri, S. R., Mishra, S. K., Arora, S., Aggarwal, A., Sharma, S., Jain, E., Akgul, M., Acosta, A. M., Pattnaik, N., Kaushal, S., Baisakh, M., Routa, S., Shaker, N., Dhillon, J., Parwani, A. V., Williamson, S. R., …, & Cheng, L. (2026). Molecular characterization of clear cell adenocarcinoma of the urinary bladder. Histopathology. https://doi.org/10.1111/his.70096
Vancouver
Jha S, Lobo A, Sangoi AR, Kandukuri SR, Mishra SK, Arora S, et al. Molecular characterization of clear cell adenocarcinoma of the urinary bladder. Histopathology. 2026. doi:10.1111/his.70096
BibTeX
@article{Jha2026,
author = {Jha, Shilpy and Lobo, Anandi and Sangoi, Ankur R and Kandukuri, Shivani R and Mishra, Sourav K and Arora, Samriti and Aggarwal, Aditi and Sharma, Shivani and Jain, Ekta and Akgul, Mahmut and Acosta, Andres M and Pattnaik, Niharika and Kaushal, Seema and Baisakh, Manas and Routa, Sudhasmita and Shaker, Nada and Dhillon, Jasreman and Parwani, Anil V and Williamson, Sean R and Mohanty, Sambit K and Cheng, Liang},
title = {Molecular characterization of clear cell adenocarcinoma of the urinary bladder},
journal = {Histopathology},
year = {2026},
doi = {10.1111/his.70096}
}
EUVIMED